Next Article in Journal
Feasibility of Nonintubated Anesthesia for Lumboperitoneal Shunt Implantation
Previous Article in Journal
Assessment of Dynamic Knee Valgus between Lateral Step-Down Test and Running in Female Runners with and without Patellofemoral Pain Using Two-Dimensional Video Analysis
Article

Further Validation of the Crohn’s and Ulcerative Colitis Questionnaire-32 (CUCQ-32) to Measure the Quality of Life in Patients Treated with Biologics Therapy

1
St Mark’s Hospital, Watford Road, Harrow, London HA1 3UJ, UK
2
Medical School, Swansea University, Swansea SA2 8PP, UK
3
Western General Hospital, Edinburgh EH4 2XU, UK
*
Author to whom correspondence should be addressed.
Academic Editor: Anna Capasso
Clin. Pract. 2022, 12(3), 436-448; https://doi.org/10.3390/clinpract12030048
Received: 27 April 2022 / Revised: 6 June 2022 / Accepted: 9 June 2022 / Published: 10 June 2022
Background: Crohn’s and Ulcerative Colitis Questionnaire-32 (CUCQ-32) is a validated questionnaire to measure the quality of life (QoL) in Inflammatory Bowel Disease (IBD). However, it does not have stoma-specific questions and can be lengthy. This study aimed to validate a subset of the CUCQ-32 that would be suitable for patients with a stoma. Methods: Baseline data were collected from a cohort of patients with acute ulcerative colitis who were participating in the CONSTRUCT multicentre clinical trial. A subset of the CUCQ-32 questions was selected by stepwise regression. Further validation was examined using data from the UK IBD biological therapies audit. Construct validity was carried out using the EuroQol 5 dimensions (EQ5D) questionnaire, Simple Clinical Colitis Activity Index (SCCAI), and the Harvey–Bradshaw Index (HBI). Results: Using the data from 124 patients, a short-version questionnaire (CUCQ-12) was developed. Data from 484 patients with IBD (382 patients with Crohn’s disease, 76 patients with ulcerative colitis, and 26 patients with IBD-Unclassified) and 61 patients with stoma provided further validation of the CUCQ-12. A literature review and an expert focus group identified supplementary stoma-specific questions for the CUCQ-12+. The CUCQ-12+ demonstrated excellent internal consistency (Cronbach’s α = 0.86); established effective reproducibility (intra-class correlation coefficient = 0.74); correlated well with the EQ5D (r= −0.48), HBI (r = 0.45), and SCCAI (r = 0.43); and represented good responsiveness statistics (>0.5). Conclusions: CUCQ-12+ is a valid and reliable QoL measure used for all patients with IBD in clinical practice, including patients with a stoma. View Full-Text
Keywords: quality of life; Inflammatory Bowel Disease; Crohn’s disease; ulcerative colitis; Patients Reported Outcomes quality of life; Inflammatory Bowel Disease; Crohn’s disease; ulcerative colitis; Patients Reported Outcomes
MDPI and ACS Style

Alrubaiy, L.; Sikafi, R.; Hutchings, H.A.; Arnott, I.; Williams, J.G. Further Validation of the Crohn’s and Ulcerative Colitis Questionnaire-32 (CUCQ-32) to Measure the Quality of Life in Patients Treated with Biologics Therapy. Clin. Pract. 2022, 12, 436-448. https://doi.org/10.3390/clinpract12030048

AMA Style

Alrubaiy L, Sikafi R, Hutchings HA, Arnott I, Williams JG. Further Validation of the Crohn’s and Ulcerative Colitis Questionnaire-32 (CUCQ-32) to Measure the Quality of Life in Patients Treated with Biologics Therapy. Clinics and Practice. 2022; 12(3):436-448. https://doi.org/10.3390/clinpract12030048

Chicago/Turabian Style

Alrubaiy, Laith, Rafid Sikafi, Hayley A. Hutchings, Ian Arnott, and John G. Williams. 2022. "Further Validation of the Crohn’s and Ulcerative Colitis Questionnaire-32 (CUCQ-32) to Measure the Quality of Life in Patients Treated with Biologics Therapy" Clinics and Practice 12, no. 3: 436-448. https://doi.org/10.3390/clinpract12030048

Find Other Styles

Article Access Map by Country/Region

1
Back to TopTop